News

B.C. funds new cancer treatment test

By The Canadian Press

VANCOUVER - B.C. has become the latest province to fund a test that can help determine whether patients with a certain type of early stage breast cancer could benefit from chemotherapy.

California-based Genomic Health says the BC Cancer Agency has agreed to fund the company's Oncotype DX test.

The test, which costs US$4,300, examines genes within breast cancer tumours to predict which patients would benefit from chemotherapy.

Conversely, the test is also used to predict which patients would see little or no benefit from chemotherapy.

The funding applies to patients that meet a list of criteria, including that they have early stage, node-negative, estrogen receptor-positive invasive breast cancer.

The test is already funded by provincial governments in Alberta, Ontario, Quebec, Saskatchewan, and Newfoundland and Labrador.

We encourage an open exchange of ideas on this story's topic, but we ask you to follow our guidelines for respecting community standards. Personal attacks, inappropriate language, and off-topic comments may be removed, and comment privileges revoked, per our Terms of Use. Please see our FAQ if you have questions or concerns about using Facebook to comment.

You might like ...

Green MLA Weaver to seek leadership
 
Richmond urges RCMP to rethink ‘impractical’ policy
 
Green carts slated for rollout to apartments
MLA John Yap on medical leave after heart surgery
 
Sands took on ALS with positivity
 
Police look for help in finding suspect in string of robberies
UPDATE: Woman assaulted in Surrey and suffers head injury, man arrested
 
New program boosts technology and agriculture in Mission
 
Slopes for Hope at Hemlock Valley Resort

Community Events, January 2015

Add an Event

Read the latest eEdition

Browse the print edition page by page, including stories and ads.

Jan 28 edition online now. Browse the archives.